Featured Research

from universities, journals, and other organizations

Antibody response linked with rejection in pediatric kidney transplant recipients

Date:
February 28, 2013
Source:
American Society of Nephrology
Summary:
A transplanted kidney has a finite life expectancy because it often becomes the target of the recipient's immune system, which may mount antibodies that attack the organ. Because there is a critical need to extend the life of transplanted organs -- especially in children, who can face two to three kidney transplants in their lifetime -- researchers recently examined the role of this antibody-mediated injury in rejection and the effectiveness of medications to prevent it.

A transplanted kidney has a finite life expectancy because it often becomes the target of the recipient's immune system, which may mount antibodies that attack the organ. Because there is a critical need to extend the life of transplanted organs -- especially in children, who can face two to three kidney transplants in their lifetime -- researchers recently examined the role of this antibody-mediated injury in rejection and the effectiveness of medications to prevent it.

Their findings are reported in the Journal of the American Society of Nephrology (JASN).

Minnie Sarwal, MD, FRCP, PhD (California Pacific Medical Center) and her colleagues mapped the antibody immune response in 130 children who received kidney transplants through 12 different US transplant programs participating in a trial comparing complete steroid avoidance after transplantation and standard steroid therapy after transplantation. (Some patients received long-term steroids after transplantation as a treatment to potentially protect the new organ from antibody-mediated injury, while others received no steroids.) Patients were monitored for two years after transplantation.

"The development of antibodies were confirmed to injure the transplant, though the incidence of this antibody-mediated injury to the transplant was quite low at only about 6%," said Dr. Sarwal. Patients with these antibodies were more likely to experience organ injury and rejection than patients without these antibodies.

Also, steroids did not seem to provide a benefit. "There was no difference in the immune response in children who did not receive steroids, though there was a huge benefit in their growth, in lower blood pressures, and lower cholesterol levels, supporting the importance of avoiding steroids in children after transplantation wherever possible," she added.

The researchers recommend monitoring recipients for the presence of antibodies directed against transplanted organs at various stages and customizing immunosuppressive treatments to prevent rejection.

Study co-authors include Abanti Chaudhuri, MD, Mikki Ozawa, Matthew Everly, Robert Ettenger, MD, Vikas Dharnidharka, MD, Mark Benfield, MD, Robert Mathias, MD, Anthony Portale, MD, Ruth McDonald, MD, William Harmon, MD, David Kershaw, MD, V. Matti Vehaskari, MD, Elaine Kamil, MD, H. Jorge Baluarte, MD, Bradley Warady, MD, Li Li, Tara Sigdel, Szu-chuan Hsieh, Hong Dai, Maarten Naesens, Janie Waskerwitz, RN, Oscar Salvatierra Jr, MD, and Paul Terasaki, PhD.


Story Source:

The above story is based on materials provided by American Society of Nephrology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Abanti Chaudhuri, Mikki Ozawa, Matthew J. Everly, Robert Ettenger, Vikas Dharnidharka, Mark Benfield, Robert Mathias, Anthony Portale, Ruth McDonald, William Harmon, David Kershaw, V. Matti Vehaskari, Elaine Kamil, H. Jorge Baluarte, Bradley Warady, Li Li, Tara K. Sigdel, Szu-chuan Hsieh, Hong Dai, Maarten Naesens, Janie Waskerwitz, Oscar Salvatierra Jr, Paul I. Terasaki, and Minnie M. Sarwal. The Clinical Impact of Humoral Immunity in Pediatric Renal Transplantation. Journal of the American Society of Nephrology, 2013; DOI: 10.1681/ASN.2012070663

Cite This Page:

American Society of Nephrology. "Antibody response linked with rejection in pediatric kidney transplant recipients." ScienceDaily. ScienceDaily, 28 February 2013. <www.sciencedaily.com/releases/2013/02/130228171452.htm>.
American Society of Nephrology. (2013, February 28). Antibody response linked with rejection in pediatric kidney transplant recipients. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2013/02/130228171452.htm
American Society of Nephrology. "Antibody response linked with rejection in pediatric kidney transplant recipients." ScienceDaily. www.sciencedaily.com/releases/2013/02/130228171452.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins